Osseointegration challenges of dental implants in dialysis-dependent chronic kidney disease patients

Abstract

Dental implant therapy in dialysis-dependent chronic kidney disease (CKD) patients presents significant osseointegration challenges due to systemic metabolic disturbances inherent to end-stage renal disease. Renal osteodystrophy, characterized by abnormal bone turnover, mineralization defects, and secondary hyperparathyroidism, critically compromises alveolar bone quality and remodeling capacity essential for implant stability. Elevated parathyroid hormone levels induce excessive bone resorption, while hyperphosphatemia and hypocalcemia disrupt hydroxyapatite crystallization, impairing the bone-implant interface formation. Uremic toxins accumulate despite dialysis, inducing chronic inflammation and oxidative stress that suppress osteoblast activity and angiogenesis while promoting osteoclastogenesis. Additionally, frequent comorbidities, including diabetes, hypertension, and anemia further compromise microcirculation and tissue healing. Anticoagulant use during hemodialysis increases perioperative bleeding risks, potentially disrupting early clot formation and cellular migration at the surgical site. Although dental implants remain a viable rehabilitation option for edentulous CKD patients, success rates are generally lower compared to healthy populations, with higher incidences of marginal bone loss and late failures. Careful patient selection, optimized dialysis timing around surgery, stringent control of calcium-phosphate products and parathyroid hormone levels, and also extended healing periods are recommended clinical strategies. Limited long-term prospective studies specifically addressing implant outcomes in this population highlight an evidence gap requiring further investigation. Multidisciplinary coordination between nephrologists and implantologists is essential to mitigate risks. Though not an absolute contraindication, implant placement in dialysis-dependent patients demands thorough preoperative assessment of bone metabolism markers, individualized surgical protocols, and realistic patient counseling regarding potentially prolonged osseointegration timelines and guarded long-term prognosis compared to non-renal compromised individuals.

Keywords: Osseointegration, Vitamin D, Parathyroid hormone, End-stage renal disease, Fibroblast growth factor, Chronic kidney disease, Renal osteodystrophy, Secondary hyperparathyroidism